Podcasts about mounjaro

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Can you still eat at restaurants while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Absolutely.One of the biggest misconceptions about GLP-1 medications is that you have to avoid restaurants, skip vacations, or order the “healthiest” item on the menu to lose weight. The truth? Long-term success comes from learning how to navigate real life—not avoiding it.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna Beasley shares her simple, evidence-based strategy for eating out while staying true to your health goals. You'll learn how to build balanced meals, listen to your body's fullness cues, and enjoy restaurant meals without guilt, stress, or overthinking every bite.Whether you're headed to date night, a family dinner, a work lunch, or vacation, this episode will help you feel confident ordering at almost any restaurant while taking a GLP-1.In this episode, you'll learn:How to order at restaurants while taking a GLP-1A simple meal-building formula you can use almost anywhereWhy you don't need to avoid eating out to be successfulHow to prioritize protein without obsessing over caloriesWhat to do when you feel full halfway through your mealTips for reducing nausea or digestive discomfort when dining outHow to navigate appetizers, desserts, and drinks without guiltWhat to say when people comment on how much—or how little—you're eatingIf you've ever searched “What should I order on Ozempic?”, “Can I eat at restaurants on Wegovy?”, or “How do I eat out on a GLP-1?”, this episode is for you.

L'internet adore les explications simples sur l'obésité. Mangez moins, bougez plus, faites preuve de volonté. Dans cet épisode, un chirurgien bariatrique et une psychologue clinicienne expliquent pourquoi cette vision ne tient pas compte de la réalité humaine ni de la biologie. Si vous vous êtes déjà senti jugé en raison de votre poids, ou si vous vous êtes déjà reproché d'avoir repris du poids, cette conversation remplace la culpabilité par la science.Nous abordons l'obésité comme une maladie chronique influencée par la génétique, les hormones, le métabolisme, les médicaments, le stress, les mécanismes d'adaptation et un environnement rempli d'aliments peu coûteux et hyperappétents. Vous découvrirez que les interventions comme la gastrectomie en manchon et le pontage gastrique font bien plus que réduire la taille de l'estomac. Elles modifient aussi les hormones de la faim et de la satiété, notamment la ghréline et le GLP, tout en permettant de mieux comprendre des concepts comme la théorie du point d'équilibre pondéral, ainsi que les raisons pour lesquelles le corps résiste souvent à une perte de poids durable.Nous discutons également des aspects psychologiques de l'obésité, notamment l'alimentation émotionnelle, le bruit alimentaire, la stigmatisation liée au poids, les changements d'identité après la chirurgie et les raisons pour lesquelles mesurer le succès uniquement avec le chiffre sur la balance peut devenir contre-productif. Vous découvrirez aussi des stratégies concrètes, comme prioriser les protéines et les fibres pour favoriser la satiété et réduire la faim, ainsi que des approches réalistes pour bâtir des habitudes durables.Enfin, nous parlons des médicaments agonistes du GLP, 1, comme Wegovy, Ozempic, Mounjaro et Zepbound. Nous expliquons leur rôle dans le traitement de l'obésité, pourquoi ils sont souvent mal compris et pourquoi les meilleurs résultats sont obtenus lorsqu'ils sont combinés à des changements durables des habitudes de vie et à un suivi régulier.Si cette conversation vous a été utile, abonnez-vous, laissez un avis et partagez cet épisode avec une personne qui pourrait bénéficier d'une vision plus compatissante et fondée sur les données scientifiques de l'obésité.Go check out my website for tons of free resources on how to transition towards a healthier diet and lifestyle.You can download my free plant-based recipes eBook and a ton of other free resources by visiting  the Digital Downloads tab of my website at https://www.plantbaseddrjules.com/shopDon't forget to check out my blog at https://www.plantbaseddrjules.com/blog You can also watch my educational videos on YouTube at https://www.youtube.com/channel/UCMpkQRXb7G-StAotV0dmahQCheck out my upcoming live events and free eCourse, where you'll learn more about how to create delicious plant-based recipes: https://www.plantbaseddrjules.com/Go follow me on social media by visiting my Facebook page and Instagram accountshttps://www.facebook.com/plantbaseddrjuleshttps://www.instagram.com/plantbased_dr_jules/Last but not least, the best way to show your support and to help me spread my message is to subscribe to my podcast and to leave a 5 star review on Apple and Spotify!Thanks so much!Peace, love, plants!Dr. Jules 

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

Ozempic is helping millions lose weight—but what if it's also causing a hidden form of muscle loss most people never see coming?"Ozempic feet" has become a viral term, but the real concern isn't just how your feet look—it's what rapid weight loss may be doing to your muscle mass, strength, metabolism, and long-term health.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the truth behind Ozempic muscle loss, why it happens, who is most at risk, and the science-backed strategies to rebuild lean muscle while protecting your health.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication—or considering one—this is information you need before your next step.Supplements Featured In This Episode:• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast®  https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz Not sure what food to eat and avoid? This guide is for you.⬇️

Few prescription drugs have generated as much excitement as the new generation of weight-loss drugs, commonly called “GLP-1” medications. You've probably heard about Ozempic, Wegovy, Zepbound, and Mounjaro, even if you don't want to lose weight.In this episode: How do these drugs work? How to deal with the sometimes-unpleasant side effects? What has the GLP-1 family of drugs been proven to do, and what could they be used for in the future? Plus, details about a new Medicare program that now covers these drugs when prescribed for weight loss for those who qualify.Not a Checkbook member? ⁠⁠⁠⁠⁠⁠Sign up for a free 30-day trial to access all of our unbiased ratings⁠⁠⁠⁠⁠⁠.

Uno de cada diez adultos en Estados Unidos utiliza ya un fármaco inyectable para perder peso y su uso no deja de crecer en Europa. El auge de medicamentos como Mounjaro y Ozempic está transformando la industria farmacéutica y cambiando la forma de abordar la obesidad. En Hora 25 de los Negocios conversamos con el CEO de Eli Lilly en España sobre el futuro del sector y el momento que vive la compañía, que acaba de convertirse en la primera farmacéutica del mundo en alcanzar el billón de dólares de valor en bolsa.

Uno de cada diez adultos en Estados Unidos utiliza ya un fármaco inyectable para perder peso y su uso no deja de crecer en Europa. El auge de medicamentos como Mounjaro y Ozempic está transformando la industria farmacéutica y cambiando la forma de abordar la obesidad. En Hora 25 de los Negocios conversamos con el CEO de Eli Lilly en España sobre el futuro del sector y el momento que vive la compañía, que acaba de convertirse en la primera farmacéutica del mundo en alcanzar el billón de dólares de valor en bolsa.

¿Alguna vez has sentido que tu mente libra una batalla campal cada vez que ves comida deliciosa? ¿Por qué para algunas personas comer menos es "fácil" y para otras es una tortura diaria?En este episodio no venimos a hablar de un fármaco de moda. Usamos a Ozempic, Mounjaro y la revolución de los GLP-1 como un caballo de Troya para desvelar el secreto mejor guardado de tu cuerpo: cómo funciona realmente la neurobiología del hambre.Acompáñame a destruir de una vez por todas el mito de la "fuerza de voluntad" y a entender qué es el "food noise" (ese ruido mental constante con la comida) y cómo la ciencia ha logrado apagarlo. Además, analizamos los últimos datos de este 2026: qué es el "muro del año", por qué estos fármacos pueden dejar de funcionar y cómo evitar el temido efecto rebote protegiendo tu masa muscular.En este episodio aprenderás:

Has your weight loss suddenly stopped on Ozempic, Wegovy, Mounjaro, or Zepbound?If the scale hasn't moved in weeks and you're wondering whether your GLP-1 has stopped working, you're not alone. Weight loss plateaus are one of the most common—and frustrating—parts of the GLP-1 journey.The good news? A plateau doesn't automatically mean you've done something wrong or that your medication has failed.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna explains why weight loss plateaus happen, what your body is actually doing, and the evidence-based questions she asks clients before making any changes.We'll cover:What actually counts as a weight loss plateauWhy weight loss naturally slows over timeThe difference between normal weight fluctuations and a true stallCommon reasons GLP-1 weight loss plateaus happenHow protein, hydration, fiber, sleep, stress, and movement influence progressWhy eating less isn't always the answerWhen it may be time to talk with your healthcare providerThe mindset shift that helps you move through a plateau without panicIf you've been asking yourself, “Why did my weight loss stop on Ozempic?” or “Why isn't my GLP-1 working anymore?” this episode will help you understand what may be happening and what to focus on next.

¿Son los nuevos fármacos para perder peso la solución definitiva o una trampa con fecha de caducidad? En el caso real de hoy analizamos la historia de una paciente de 45 años, con un cargo directivo de alta responsabilidad y altos niveles de estrés, que decidió pincharse Mounjaro buscando una vía rápida para adelgazar antes de un evento. Soportó meses de náuseas constantes, vómitos semanales y reflujo severo bajo la falsa creencia de que "si dolía y sufría, es que estaba funcionando". Tras suspender el tratamiento por intolerancia gástrica, el hambre voraz regresó, provocando un durísimo efecto rebote en el que recuperó todo lo perdido más 6 kilos de regalo. Descubre cómo abordamos en consulta este caso para reparar su metabolismo, sanar su relación con la comida y devolverle la libertad mental.En este episodio aprenderás:Por qué fármacos como Mounjaro u Ozempic actúan como un "tapón" temporal pero no solucionan los problemas de base si no hay reeducación nutricional.El peligro oculto de la pérdida drástica de masa muscular y cómo esto destruye y ralentiza tu metabolismo.Herramientas de psiconutrición para reaprender a escuchar las señales reales de hambre y saciedad tras una supresión artificial del apetito.Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

Today we're tackling one of the hottest topics in medicine, nutrition, and weight loss. GLP-1 medications.You know them by names like Ozempic, Wegovy, Mounjaro, and Zepbound. You've seen the commercials.You've heard the celebrity stories. You probably know someone taking one. Maybe you're taking one yourself.These medications have transformed the conversation around weight loss, and for many people they have been life-changing. But they've also raised some important questions. Can we naturally stimulate our own GLP-1? And now, Can fasting provide some of the same benefits?And is the future of weight management medication, lifestyle, or a combination of both? Fasting & GLP-1

Los tratamientos con agonistas GLP-1 han supuesto un antes y un después en el manejo de la obesidad. Pero, como ocurre con cualquier herramienta terapéutica, no todo consiste en perder peso y, aunque estos fármacos ofrecen muy buenos resultados, también conllevan una gran responsabilidad: evitar perder salud metabólica por el camino.Porque, ¿qué pasa con el músculo? ¿Por qué es tan importante asegurar un adecuado consumo de proteínas? ¿Qué papel juega la fibra cuando comemos menos? ¿Y qué micronutrientes conviene vigilar, como el hierro, la vitamina B12, la vitamina B1, vitamina D o la colina?En este episodio hablamos de la parte del tratamiento de la que menos se habla: cómo conseguir que la pérdida de peso sea, además, una pérdida de grasa… y no de salud. Porque adelgazar no debería significar perder fuerza, funcionalidad ni aumentar el riesgo de déficits nutricionales.Si tú o alguien cercano está siguiendo un tratamiento con un agonista GLP-1, creo que este episodio puede ayudaros a entender cómo acompañarlo desde la fisiología y la evidencia científica para obtener los mejores resultados.Y si, además, quieres profundizar en otros aspectos relacionados con estos tratamientos, te recomiendo escuchar también los episodios 77 y 111, donde encontrarás información complementaria que te ayudará a entender mejor su funcionamiento, sus beneficios y cómo utilizarlos de la forma más segura y eficaz posible.Como siempre digo: saber más para temer menos y elegir mejor.Para mas información ya sabéis que me tenéis en mi instagram @isabelvina dónde te comparto contenido diario Mi TikTok @isabelvinabasEn mi canal de YouTube Canal YoutubeY los suplementos formulados por mi en mi web  Mi web

In the western world, richer people tend to be thinner – especially women. But does wealth make people thin, or does being thin make them wealthy? And could the rise of weight-loss drugs such as Mounjaro and Wegovy give people – especially women – greater control over their economic outcomes? Soumaya speaks to Harvard professor Rebecca Diamond, the author of a new working paper that finds female users of GLP-1 drugs are more likely to find jobs and romantic partners. Soumaya also speaks to FT consumer editor (and GLP-1 user) Claer Barrett to discuss the drugs' effects on consumer habits – and the economy at large.Subscribe to Soumaya's show on Apple, Spotify, Pocket Casts or wherever you listen.Further reading: The economics of women's weightDoes the weight-loss revolution show up in the data?The challenges of a weight-loss economyPresented by Soumaya Keynes. Produced by Mischa Frankl-Duval. Original music and sound design by Breen Turner. Andrew Georgiades is the broadcast engineer. Manuela Saragosa is the executive producer. Flo Phillips if the FT's head of audio.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

Have you ever looked in the mirror and wondered, "Why is it so much harder to lose weight than it used to be?" Maybe you've tried the diets... counted the calories... exercised faithfully... only to watch the scale refuse to budge. What if the problem isn't a lack of willpower? What if we've been asking the wrong question all along?Today on Call IT in With Dar, I'm joined by Dr. William Summers, a physician with more than 36 years of experience helping people understand the science behind obesity. As a board-certified OB/GYN and medical weight management specialist, Dr. Summers believes it's time we stop blaming ourselves and start recognizing obesity for what it truly is—a complex medical condition influenced by biology, hormones, metabolism, and our modern environment.  In this myth-busting conversation, we'll explore why obesity has become one of the greatest health challenges of our time, what new research is revealing, how medications like Ozempic and Mounjaro are changing the conversation, and most importantly, why compassion and understanding are far more powerful than guilt and shame.  Whether you're struggling with your own weight, supporting someone you love, or simply wanting to separate fact from fiction, this episode offers clarity, hope, and practical insight.  Let's come together for this important conversation about obesity! Call It in with Dar! Support the showFull Show Notes can be found at CallITInPodcast.comPhoto credit: Rebecca Lange Photography Music credit: Kevin MacLeod Incompetech.com (licensed under Creative Commons)  Production credit: Erin Schenke @ Emerald Support Services LLC.Grab Dar's Flight Deck Oracle Card DeckTake Dar's Archetype Quiz

In this episode, I'm talking about why so many attempts to change your relationship with food seem to fizzle out, even when you're motivated and genuinely want things to be different. Because constantly starting over doesn't mean you're lazy, uncommitted, or missing some magical piece of information. We're digging into the deeper reasons certain behaviors stick around, what they may actually be doing for you, and why curiosity is often far more helpful than criticism.  This conversation goes beyond meal plans and motivation and gets into the questions that most people never think to ask. Quotes "We don't lead with the question, what do we do about this? We lead with the question, what is this actually all about? It's the question that changes everything when someone is really willing to look at it, because the answer is usually not what you think it is." "Most of us are so focused on fixing the behavior that we haven't stopped to ask what the behavior is doing." "The reason change feels so hard isn't because you're weak; it's because something would have to be given up if you changed. Meaning, if the behavior is protective in some way, shape, or form, it's providing something for you." "You don't need to know the answer yet. The key is starting to think about this and removing the blame that we're pointing at ourselves and starting to ask questions." "Sometimes this isn't something that you can do alone, and that's where you might need a real person like a therapist or a dietician. Sometimes we need people who can see the patterns that we're too close to see." Frequently Asked Questions Why do I keep failing when I try to change my eating habits? Repeatedly struggling with food does not necessarily mean you lack motivation or discipline. Many behaviors serve a purpose, and understanding what they are providing can help create lasting change.   Why do I sabotage myself around food? What feels like self-sabotage is often a protective pattern. Behaviors around food may be helping you cope with emotions, stress, shame, or fear, even when those behaviors are no longer serving you well.   Why is giving up dieting so scary? For many people, dieting feels tied to safety, control, belonging, or fear of weight gain. Letting go of those rules can bring up emotions and beliefs that deserve attention and support.   What does fear of weight gain really mean? Fear of weight gain often goes beyond the number on the scale. It can be connected to shame, past experiences, fears of rejection, or beliefs about worth and acceptance.   Why do I feel stuck between wanting recovery and wanting to stay the same? Feeling pulled in two directions is called ambivalence, and it is a normal part of recovery. Having conflicting feelings does not mean you're doing anything wrong.   Does structured eating help with disordered eating? Structured eating provides consistency and helps create a foundation for healing. Many people benefit from eating regularly throughout the day rather than relying on hunger cues alone in the early stages of recovery.   Do I need a therapist or a dietitian for eating disorder recovery? Support can be helpful when you're too close to your own patterns to see them clearly. A therapist or dietitian can help you understand what is driving your behaviors and provide practical tools for recovery. Resources Be sure to sign up for my weekly newsletter! Brave on Purpose! - Grab my new book here! Grab my Journal Prompts Here! Looking for a speaker for an upcoming event? Let's chat! Now accepting new clients! Find out if we're a good fit!    Episodes Mentioned: -Episode 45. Basics of Intuitive Eating -Episode 122. Ozempic, Wegovy, & Mounjaro with Laura Cipullo -Episode 133. GLP with Dr. Kim Dennis -Episode 160. Intuitive Eating Updates You Need to Know with Elyse Resch MS, RDN, CEDS-C, Fiaedp, FADA, FAND   LEAVE A REVIEW + help someone who may need this podcast by sharing this episode. Be sure to sign up for my weekly newsletter here! You can connect with me on Instagram @rachelleheinemann, through my website www.rachelleheinemann.com, or email me directly at rachelle@rachelleheinemann.com

Thought your GLP-1 medication would completely eliminate sugar cravings?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and still find yourself craving chocolate, sweets, chips, or your favorite snacks, you're definitely not alone.The truth is, cravings are much more complex than most people realize—and having cravings doesn't automatically mean your medication has stopped working.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna breaks down the science behind food cravings, explains why they can still happen while taking a GLP-1, and shares practical, evidence-based strategies to help you better understand what your body may be trying to tell you.We'll cover:Why you may still crave sugar while taking a GLP-1The difference between hunger, cravings, and food noiseHow under-eating can actually increase cravingsWhy protein matters—but isn't the entire solutionThe impact of sleep, stress, and daily habits on cravingsWhy emotional eating can still happen on a GLP-1How years of habit can influence what you craveWhen cravings may be worth discussing with your healthcare providerIf you've ever wondered, “Why am I still craving sugar on Ozempic?” or worried that cravings mean your medication has stopped working, this episode will help you understand what's actually happening—and how to respond with curiosity instead of guilt.

What if the biggest challenge isn't losing the weight... but keeping it off after Ozempic?Millions of people have turned to GLP-1 medications like Ozempic, Wegovy, and Mounjaro for life-changing weight loss. But what happens when you stop taking them? For many, the weight starts coming back faster than expected.In this episode of Accelerated Health with Sara Banta, I break down the science behind weight regain after GLP-1 medications and reveal practical strategies to help you transition off these drugs while supporting a healthy metabolism.Whether you're currently taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication—or you're thinking about stopping—this episode provides valuable insights to help you make informed decisions alongside your healthcare provider.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz Not sure what food to eat and avoid? This guide is for you.⬇️

¿Quieres dar el paso con acompañamiento profesional? Te invitamos a conocer nuestra Comunidad de mujeres Keto Real. Aprovecha ahora que tenemos 7 días gratis para probarla. Entra en https://www.skool.com/ketoreal/about y descubre un espacio donde aprenderás a transformar tu alimentación de forma real y sostenible. En este episodio de Keto Real, la dietista Cintia Morillas aborda de forma honesta el debate sobre Ozempic, Wegovy y Mounjaro. Explica que estos fármacos, que contienen semaglutida o tircepatida, reducen el apetito y facilitan comer menos, pero advierte del peligro de perder masa muscular si no se acompaña de una alimentación adecuada y entrenamiento de fuerza. Especialmente en mujeres de 40 a 60 años, donde la menopausia acelera la pérdida muscular y empeora la sensibilidad a la insulina. La alternativa que propone es una keto mediterránea bien pautada, basada en comida real, proteína suficiente y educación alimentaria. Concluye que la clave no está en demonizar estos fármacos, sino en no usarlos como sustituto de aprender a comer.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Resources for the Community:___________________________________________________________________Linktree Our Favorite ThingsNeed help appealing your GLP-1 dials? www.FindHonestCare.com/KimFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Can GLP-1s Affect Food Noise, Alcohol, and Addiction?** While Kim takes time away following the passing of her sister, we're revisiting some of our most impactful conversations. Thank you for your kindness, patience, and continued support of The Plus SideZ Podcast.We're sharing this episode because it's more relevant today than when it first aired. Since then, research has expanded interest in whether GLP-1 medications may affect more than weight loss, including food noise, alcohol cravings, and other compulsive behaviors. While the science continues to evolve, so does the conversation.Licensed therapist and addiction treatment leader Dr. Joy Bracey joins community member Brenda, who shares how Mounjaro changed her relationship with food, alcohol, and smoking. Together, they discuss the brain, behavior, and why this emerging area of research is drawing growing interest.**In this episode:**• Brenda's journey with obesity, binge eating, alcohol, smoking, and Mounjaro• Food noise, binge eating, and emotional eating• GLP-1 medications, dopamine, and the brain• Alcohol cravings and addictive behaviors• Mental health, self-love, and healing• Why researchers are studying GLP-1 medications beyond weight loss*Originally recorded during Season 1. This episode reflects the information available at the time of recording. Research and clinical guidance have continued to evolve. It is intended for education and discussion only and is not medical advice. Always consult your healthcare provider regarding your individual care.*______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Started feeling hungry again on your GLP-1 and wondering if your medication has stopped working?You're not alone.One of the biggest misconceptions about Ozempic, Wegovy, Mounjaro, and Zepbound is that you should never feel hungry. But the truth is, hunger is a normal biological signal—and experiencing hunger doesn't automatically mean your GLP-1 isn't working.In this episode, Registered Dietitian and GLP-1 expert Gianna explains why appetite can change throughout your GLP-1 journey, what influences hunger beyond your medication, and how to tell the difference between normal hunger and something that may deserve a conversation with your healthcare provider.We'll discuss:Why it's normal to feel hungry on a GLP-1Whether your medication can “stop working”The difference between hunger and food noiseCommon reasons your appetite may increaseHow under-eating can actually make hunger worseThe impact of stress, sleep, hormones, and daily routines on appetiteWhen increased hunger may be a reason to talk with your healthcare providerWhy learning to trust your body's hunger cues is part of long-term successIf you've ever worried that feeling hungry means you've failed—or that your medication isn't doing its job—this episode will help you understand what's actually happening and how to respond with confidence instead of fear.

This week on the Trade Legends Podcast, landscaper and content creator Tom joins us for his long-awaited return, and he doesn't hold back. It's been nearly three years since Tom last sat in the studio, and in that time his life has changed beyond recognition. Tom opens up about the moment, two years ago to the day we recorded this, when he hit rock bottom. He talks honestly about the help he got, the people who stepped up, and how he pulled himself back. This isn't a sob story. It's one of the most genuine, hopeful conversations we've had on the podcast, and Tom tells it the way only he can. Since we last spoke, Tom has gone from around 1,000 followers to closing in on 24,000, picked up brand deals and ambassadorships, and completely transformed how his landscaping business operates. He tried scaling up with a team of three, decided it wasn't for him, and went back to working solo, finishing every job ahead of schedule and making just as much money with far less stress. He also lost seven and a half stone. At his heaviest, he was 22 stone, and the weight he lost was equivalent to the combined weight of his two boys. We touch on Mounjaro, the journey that came with it, and why there's a part two coming on that topic alone. We round off with Tom's take on dodgy customers versus dodgy tradespeople, why he now takes a 50% deposit without exception, and what he'd tell himself ten years ago, starting out in the trade. If you're going through a difficult time, please reach out. Samaritans are available 24/7 on 116 123.

De kilo's vliegen eraf bij mensen die afvallen met middelen als Ozempic, Mounjaro en Wegovy. Door de spuiten te zetten heb je minder honger en val je af. Maar mensen die het gebruiken zeggen ook andere dingen te merken. Zo zouden ze ook effect hebben op hart en vaten, op slaapapneu en zelfs kunnen helpen voor hiv-patienten. Online gaan mensen nog verder: bijvoorbeeld ook migraine zou verholpen worden door middelen als Ozempic. Die bijvangst van het medicijn fascineerde Nieuwsuur-verslaggever Lune van der Meulen en ze dook deze week in de afvalrevolutie die gaande is. Het grappige is dat afvallen een bijvangst was van deze middelen, want ze zijn eigenlijk ontwikkeld voor diabetes. Welke bijvangst die nu wordt opgemerkt is wetenschappelijk aangetoond? En wat betekent dat voor het potentieel van deze afvalmedicijnen? In de serie is naast deze bijvangst ook aandacht besteed aan stoppen met afvalmedicatie (https://nos.nl/nieuwsuur/video/2620128-stoppen-met-afslankmedicijnen-en-dan) en de eisen voordat je mag beginnen (https://nos.nl/nieuwsuur/video/2619839-afslankmedicijn-ultiem-wondermiddel) die veel mensen omzeilen. Reageren? Mail naar dedag@nos.nl (mailto:dedag@nos.nl) Presentatie & montage: Marco Geijtenbeek Redactie: Rosanne Sies

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why aren't there more medical insurance plans that cover alternative medicine? Solutions for Long Covid; MK7 vitamin K slows arterial calcification; Keto diet shows promise for treatment of anorexia; It's not so much salt restriction—it's the dietary sodium/potassium ratio in hypertension; Study finds multivitamins don't keep you from getting Covid—but when you get it, it's milder; Incidence of social anxiety disorder is soaring among young people.

If I could go back and start my GLP-1 journey all over again, there are a lot of things I would do differently.Not because I regret taking a GLP-1—but because there were lessons I had to learn through experience that I wish someone had told me from the very beginning.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 user Gianna Beasley shares the biggest things she wishes she knew before starting Ozempic, Wegovy, Mounjaro, and GLP-1 medications, including the nutrition, mindset, and lifestyle lessons that made the biggest difference.We're covering:The mistakes I made early in my GLP-1 journeyWhy protein matters more than most people realizeThe importance of hydration and side effect managementWhy I wish I focused less on the scale and more on strengthThe mental health and mindset work I wish I had done soonerWhy comparison is one of the fastest ways to sabotage your progressWhat actually matters for long-term success on a GLP-1The advice I would give myself if I were starting over todayWhether you're considering a GLP-1, just getting started, or have been taking one for a while, this episode will help you avoid common pitfalls and focus on what truly supports your health and success.

Professor Donal O'Shea, specialist in obesity, responds to the National Centre for Pharmacoeconomics comments that Mounjaro could be deemed cost effective.

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

Ozempic, Wegovy and Mounjaro can help people lose weight. But what should you eat on GLP-1 drugs to avoid side effects, protect muscle, and maintain results long term? In this episode, Dr Federica Amati, ZOE's Head Nutritionist and author of The Appetite Reset, explains how these drugs work, why many people struggle with side effects, and why losing weight does not automatically mean better health. You'll learn why the weight lost may not be fat, why nutrient deficiencies, dehydration and muscle loss can become a risk, and what to eat before, during and after treatment. Federica shares four practical principles to help reduce side effects, protect lean mass, improve diet quality and support long-term health whether you stay on these medications or eventually stop taking them. Millions of people are now using GLP-1 drugs. But if these medications reduce appetite so effectively, how do you make sure your body still gets the nutrients it needs?

The GLP-1 conversation has completely changed the wellness world. What started as a diabetes medication is now being talked about for weight loss, metabolism, cravings, inflammation, and even longevity.But as more people jump on medications like Ozempic, Wegovy, and Mounjaro, some important questions are getting overlooked. .  .Today, we're talking about:The hidden mistake that could make your weight loss backfireWhy some people lose more than just body fat, but lean tissueThe nutrient strategy experts say becomes even more important on GLP-1 medicationsThe surprising symptom many people can blame on the medication itself (but could not be)How to protect your metabolism while losing weightNatural ways to support your body's own GLP-1 productionThe connection between your gut bacteria, appetite, and cravingsWhy sleep may be playing a bigger role than you realizePlus . . . today's feelgood thing.Big thanks to our sponsor, ITL Health.More information on their magnesium formulations, designed with bioavailability in mind, can be found here:https://itlhealth.ca/Thank you for being a part of this space! xo

This episode explores how to use GLP-1 medications like semaglutide/Ozempic and tirzepatide/Mounjaro safely and effectively. Dr. Mike Hart and Dr. Christle Guevarra Do discuss once-weekly dosing, individualized titration, optimal dose selection, food noise, appetite suppression, and the risks of dosing mistakes with vials or gray-market peptides. They also cover why resistance training, protein, fiber, and realistic nutrition habits are essential for preserving muscle and maintaining results. The conversation expands into GLP-1 benefits beyond weight loss, including cardiovascular protection, inflammation, autoimmune flares, addiction-related behaviors, alcohol cravings, libido, menstrual cycles, PCOS, sleep apnea, and what to expect when stopping the medication. Dr. Christle Guevarra Do is a physician focused on obesity medicine, GLP-1 education, weight management, and sustainable lifestyle change. Drawing from both her clinical experience and her own long-term use of GLP-1 medication, she helps patients understand how these medications fit into the bigger picture of long-term health. Her approach emphasizes individualized care, strength training, nutrition, behavior change, and realistic maintenance strategies rather than quick fixes. In this episode, she shares practical guidance for using GLP-1s responsibly while protecting muscle, managing hunger, and building habits that support lasting results. Dr. Christle Guevarra Website https://www.drchristle.com/ Dr. Christle's Free GLP-1 Guide https://www.drchristle.com/glp1-guide Dr. Christle Instagram https://www.instagram.com/dr.christle/ Ozempic — semaglutide https://www.ozempic.com/ Wegovy — semaglutide for weight management https://www.wegovy.com/ Mounjaro — tirzepatide https://mounjaro.lilly.com/ Zepbound — tirzepatide for weight management / sleep apnea https://zepbound.lilly.com/ FDA: Concerns With Unapproved GLP-1 Drugs https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Retatrutide Clinical Trial Info https://clinicaltrials.gov/study/NCT05882045 Vyvanse — lisdexamfetamine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad Creatine — NIH Supplement Info https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ Psyllium Husk / Fiber — MedlinePlus https://medlineplus.gov/druginfo/meds/a601104.html Berberine — NCCIH https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know Tesamorelin — MedlinePlus https://medlineplus.gov/druginfo/meds/a611035.html CJC-1295 — PubMed Research https://pubmed.ncbi.nlm.nih.gov/16352683/ Ipamorelin — PubMed Research https://pubmed.ncbi.nlm.nih.gov/9849822/ FDA: Peptides / Compounding Safety Concerns https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Oura Ring https://ouraring.com/ White Claw https://www.whiteclaw.com/   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:45 Weekly Dosing Debate 03:41 Starting Dose Basics 06:28 Pens vs Vials Safety 08:37 Finding Your Sweet Spot 11:01 Nighttime Binge Window 13:32 Lifestyle Work Still Matters 14:30 Benefits Beyond Weight 17:27 Libido and Low Calories 22:26 Alcohol Hits Different 24:59 Cancer Claims Reality Check 26:59 Strength Training Priority 29:06 Supplements and Creatine 29:38 Creatine Protein Fiber Basics 31:50 Berberine Pros and Cons 32:37 Peptides Sleep and Muscle 35:28 Too Lean for GLP-1 38:52 Cycles PCOS and Fertility 40:45 Food Noise vs Appetite 44:42 Staying On or Stopping 49:19 Heart Rate and HRV Concerns 51:38 Ozempic vs Mounjaro Choices 54:45 Sleep Apnea and Wrap Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Former Navy SEAL Team 6 operator Craig "Sawman" Sawyer — founder of the nonprofit Veterans for Child Rescue — joins Mike Vera on the Healthy & Awake Podcast to share his firsthand assessment of child trafficking in America: how he says it operates, why he believes it stays out of the headlines, and what he argues regular people can do about it. One of the heavier conversations we've had on the show, and one of the most important.

O Grupo SmartFit se tornou um negócio multibilionário, com mais de 2 mil unidades em 16 países e um modelo de negócios que está transformando o mercado de fitness e bem-estar.Neste episódio do Economia & Negócios, Patricia Chaccur e José Inácio Pilar conversam com Cristina Duclos, CMO Global do Grupo SmartFit, sobre a estratégia por trás da expansão acelerada da empresa, o posicionamento das suas diferentes marcas, o papel da tecnologia e da inteligência artificial na experiência dos alunos e a evolução do fitness para um ecossistema completo de wellness.A executiva também explica por que as canetas emagrecedoras não estão reduzindo a demanda por academias, como a geração Z está mudando a relação com atividade física e por que a SmartFit quer se tornar uma das marcas mais admiradas do Brasil.Entre os temas da entrevista:Como o Grupo SmartFit ultrapassou 2 mil academias em 16 paísesA estratégia de expansão internacional do grupo - O posicionamento das marcas SmartFit, Bioritmo, Nation CT, Velocity e Vidya StdudioInteligência artificial aplicada ao fitness e ao atendimentoO impacto de Ozempic e Mounjaro no mercadoWellness, longevidade e saúde socialO futuro das academias nos próximos anosApoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:  https://assine.oantagonista.com.br/  Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #SmartFit #EconomiaENegocios #SucessoEmpresarial #ModeloDeNegocios #Ozempic #GeracaoZ #TecnologiaEHealth #AcademiaSmartfit #MercadoFitness #Empreendedorismo

durée : 00:38:55 - Questions du soir : le débat - par : Mattéo Caranta - Depuis le 15 juin 2026, les médicaments anti-obésité Wegovy et Mounjaro sont remboursés à hauteur de 65 % pour les personnes souffrant d'une obésité massive avec une IMC d'au moins 35. - équipe : Stéphanie Villeneuve, Mathias Mégy, Diane de Vanssay, Antoine Ayral, Juliette Mouëllic, Léa Racine - invités : Etienne Nouguez Sociologue, chercheur au CNRS et à Sciences Po (Centre de sociologie des organisations), Jean-Michel Oppert Professeur de nutrition et chef de service de Nutrition à l'hôpital Pitié-Salpêtrière (AP-HP) Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Niamh emails in raging about the amount of people taking “fat jabs” like Ozempic and Mounjaro, calling them the “lazy way out” and saying weight loss should be done the old-fashioned way — diet and exercise.Adrian argues it's nobody's business how someone loses weight, once they're healthier. Jeremy isn't having it, saying people don't deserve praise if “the jab did the work”.Stay listening for the awkward moment when Jeremy is called out by a colleague.

Worried about gaining weight back after Ozempic, Wegovy, Mounjaro, or Zepbound?You're not alone. One of the biggest concerns people have during their GLP-1 journey is what happens after the weight loss phase—and how to actually maintain their results long-term.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what sustainable weight maintenance really looks like, why maintaining weight loss is different from losing weight, and the habits that support long-term success.Because keeping weight off isn't about being perfect. It's about building routines that you can realistically maintain for years to come.We're covering:Why weight maintenance is different than weight lossCommon reasons people regain weight after losing itThe role of appetite, food noise, and long-term behavior changeWhy protein and strength training matter for maintenanceHow muscle supports long-term health and weight managementThe mindset shifts that make maintenance easierWhy all-or-nothing thinking keeps people stuckWhat successful long-term maintenance actually looks likeWhether you're currently taking Ozempic, Wegovy, Mounjaro, or Zepbound—or simply thinking ahead to the future—this episode will help you focus on the habits that support lasting results.

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

Linktree for Community ResourcesNeed help appealing a GLP-1 Insurance Denial? FindHonestCare.com/KimRo - Telehealth for GLP1 Weight ManagementThe Absolute Lies You've Heard About GLP-1s (Ozempic Myths Debunked) [REPLAY]Are you being lied to about Ozempic, Mounjaro, and Wegovy? In this special replay episode, leading obesity medicine specialists break down the biggest GLP-1 myths taking over your feed. We are reposting this crucial conversation because it is more relevant than ever. With GLP-1 price changes and expanding access options through federal programs like the Medicare GLP-1 Bridge, understanding the real science behind these medications is essential for patient advocacy.We are sharing a few favorite replay episodes right now while Kim is away on bereavement leave following the loss of her sister. We want to deeply thank our subscribers for staying engaged and supporting the show during this time.In this episode of The Plus Sidez Podcast, Kat joins Kim to sit down with obesity medicine specialists Dr. Matea Rentea and Dr. Ali Novitzki to help listeners better understand their disease and feel empowered in their healthcare journey.The Myths We Debunk:The Muscle Loss Scare: The data behind weight loss and body composition, explaining why the medication itself is not destroying your lean mass.The Willpower Narrative: Why obesity is a genetic, chronic metabolic disease rooted in brain biology, not a failure of personal willpower.The Shot-Only Illusion: How the medication works alongside your body's natural satiety signals and gut receptors.Obesity Doctor Guidance Shared:Metabolic Protection: A practical discussion on utilizing a 10-minute fitness routine and a 100-gram protein framework to maintain lean mass and support insulin sensitivity.System Navigation: Insights on navigating insurance barriers, managing prior authorizations, and advocating for proper medical care.Mental Resilience: Tools to process unsolicited comments about your weight and protect your peace from societal judgment.Episode Topics:Why We Are Replaying This Episode: Prices, Access, and UpdatesThe Insurance Landscape: Understanding Prior AuthorizationsMeet the Obesity Medicine SpecialistsDeconstructing the GLP-1 Muscle Loss NarrativeStrategies for Protecting Your MetabolismWhat the Scales Do Not Show About Insulin ResistanceNatural Satiety Triggers and Gut ReceptorsRecognizing Obesity as a Biological Chronic DiseaseAddressing Weight Stigma and External CommentarySubscribe to The Plus Sidez Podcast for science-backed episodes breaking down metabolic health, body recomposition, and the truth about weight loss.Search TagsGLP1 lies debunked, Ozempic myths, Mounjaro weight loss journey, Wegovy truth, Zepbound body recomposition, insulin sensitivity hacks, natural GLP1 boosters, treating obesity metabolic disease, plus sidez podcast, dr matea rentea, dr ali novitzki_________________________________________________________________________Join this channel to get access to perks:https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join_________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovySend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Misdiagnosed with Type 2 in her 40s, Claire went into DKA while taking Mounjaro and discovered she actually has Type 1 (LADA). Hear her UK healthcare journey. ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 20% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

President Trump uses a wide-ranging White House cabinet meeting to tout his administration's record, press Iran to make a deal, address energy concerns, and respond to the latest security scare near the White House. Former Attorney General Pam Bondi reveals she is being treated for thyroid cancer as Axios reports she is returning to the Trump administration as a liaison on the president's science and technology advisory council. A new Cleveland Clinic study finds GLP-1 drugs like Ozempic and Mounjaro are associated with slower progression in several major cancers, though researchers caution the findings do not prove the drugs caused the improved outcomes. NASA announces a new round of lunar missions and private-sector contracts aimed at testing the landers, vehicles, cargo systems, and survival infrastructure needed to return astronauts to the Moon and eventually reach Mars.   SelectQuote: Compare top‑rated life insurance options. Visit https://SelectQuote.com/megyn to get the right coverage at the right price.   Cozy Earth: This Memorial Day, visit https://www.CozyEarth.com & Use code MEGYN for up to 30% off Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 medications are changing the conversation around weight loss, metabolism, and women's health. But are we asking the right questions about long-term health?In this solo episode, Dr. Mindy Pelz breaks down the science behind GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, including what they do well, where concerns are emerging, and how fasting mimics many of the same metabolic benefits naturally.Dr. Mindy explores: • The connection between GLP-1 drugs and muscle loss • Why women over 40 need to think differently about metabolism • New research linking GLP-1s to declining bone density • How fasting impacts glucagon, ketones, and fat burning • The importance of protein, refeeding, and resistance training • Why metabolic flexibility matters more than rapid weight loss • Natural ways to stimulate your body's own GLP-1 productionThis episode is not about fear or shame. It's about helping you understand your options so you can make informed decisions for your body, your hormones, and your long-term health.For more resources related to today's episode, visit the podcast episode page: https://www.drmindypelz.com/ep341Connect with Dr. Mindy:Join Reset AcademyWatch the episodes on YouTubeFollow Dr. Mindy on InstagramSubscribe to Dr. Mindy's newsletterDisclaimer: This podcast is intended for educational and informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making changes to your diet, fasting routine, or lifestyle.

How did Ozempic, Prozac, & Viagra get their names?... It's the wild world of drug-naming.Now is the perfect time to ask your landlord to cut your rent… We got the receipts & playbook.Google's Search Bar is history's most profitable feature… But last week it got plastic surgery.Plus, the hot new vacation trend is lights-off… Dark Sky Vacations have never been brighter.$GOOG $NVO $MARNEWSLETTER:https://tboypod.com/newsletter OUR 2ND SHOW:Want more business storytelling from us? Check our weekly deepdive show, The Best Idea Yet: The untold origin story of the products you're obsessed with. Listen for free to The Best Idea Yet: https://wondery.com/links/the-best-idea-yet/NEW LISTENERSFill out our 2 minute survey: https://qualtricsxm88y5r986q.qualtrics.com/jfe/form/SV_dp1FDYiJgt6lHy6GET ON THE POD: Submit a shoutout or fact: https://tboypod.com/shoutouts SOCIALS:Instagram: https://www.instagram.com/tboypod TikTok: https://www.tiktok.com/@tboypodYouTube: https://www.youtube.com/@tboypod Linkedin (Nick): https://www.linkedin.com/in/nicolas-martell/Linkedin (Jack): https://www.linkedin.com/in/jack-crivici-kramer/Anything else: https://tboypod.com/ About Us: The daily pop-biz news show making today's top stories your business. Formerly known as Robinhood Snacks, The Best One Yet is hosted by Jack Crivici-Kramer & Nick Martell. Hosted on Acast. See acast.com/privacy for more information.

A.M. Edition for May 22. The U.S. puts arms sales to Taiwan on hold, saying the munitions and arms are needed for the war with Iran. Plus, weight-loss drugs like WeGovy and Mounjaro show a surprising ability to stall cancer. And WSJ's Laura Cooper details how bourbon distillers are facing a hangover as more Americans pinch pennies and join the ranks of the sober-curious. Daniel Bach hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Three new GLP-1 studies, why every food is suddenly "high protein," the Bethenny Frankel shoe drama blowing up Instagram, and why I'm on a ketamine table as you listen. Three new studies just shifted the GLP-1 conversation, and not in the direction women have been hearing about. Chalene digs into what's actually happening to muscle and bone density, why the rebound after coming off matters more than anyone's talking about, and the three questions every woman on Ozempic, Wegovy, Mounjaro, or Zepbound should bring to her next doctor's appointment. She also gets into why every grocery aisle suddenly screams "high protein," and why this whole moment is starting to feel suspiciously like the Snackwell cookie era. There's a simple protein target that works without tracking macros, and Chalene walks through how she's using it. Then she breaks down the Bethenny Frankel shoe drama that took over Instagram this week. What the shoe brand founder got wrong, what Bethenny got wrong, and the rules of brand partnerships that almost nobody outside the influencer world understands. Finally, a personal update. As you're listening to this, Chalene is on the table for another medically supervised ketamine treatment with Dr. Andrew Levinson. She shares why she went back for a third session, what the last journey taught her about control, and who this kind of work is really for.